DD
Sirnaomics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| STP705 | Cutaneous Squamous Cell Carcinoma in Situ (isSCC) | Phase IIb |
| STP705 (SGY-101) | Focal Fat Reduction / Medical Aesthetics | Phase I/II |
| STP707 | Multiple Solid Tumors (Pancreatic, HCC, etc.) | Phase I |
| STP122G | Anticoagulation (Factor XI) | Phase I |
| STP125G | Cardiovascular Disease (ApoC3) | Preclinical |
| STP144G | Complement-Mediated Disorders | Preclinical |
Leadership Team at Sirnaomics
DP
Dr. Patrick Lu
Founder, Executive Director, President & CEO
DX
Dr. Xiaochang (Frank) Dai
Executive Director & Chief Scientific Officer
DF
Dr. Francois Lebel
Chief Medical Officer
MM
Michael Molyneaux
Chief Financial Officer
DP
Dr. Peter Parker
Chief Administrative Officer & General Counsel